PALISADE BIO, INC.

PALI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-16.8M $-14.4M $-12.3M $-14.3M $-26.6M $-10.3M $-8.4M $-4.9M
Depreciation & Amortization $3.0K $2.0K $3.0K $143.9K $185.8K
Depreciation $3.0K $3.0K $4.0K $3.0K $29.0K $49.0K $84.0K
Amortization $63.0K $95.0K $102.0K
Stock-Based Compensation $4.0M $652.0K $624.0K $1.0M $1.9M $2.0M $880.8K $634.1K
Net Cash from Operating Activities $-10.8M $-12.2M $-11.1M $-13.4M $-14.8M $-4.8M $-7.3M $-7.7M
Investing Activities
Capital Expenditures $0 $4.0K $10.0K $0 $6.0K $1.7K
Business Acquisitions $0 $3.3M $0
Net Cash from Investing Activities $0 $-4.0K $-10.0K $-54.0K $-6.0K $5.0M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $134.4M $9.6M $11.2M $15.3M $24.6M $1.9M $6.6M $1.8M
Net Change in Cash $123.6M $-2.6M $49.0K $1.9M $9.8M $-2.9M $-672.2K $-887.8K
Free Cash Flow $-12.2M $-11.1M $-13.4M $-14.8M $-4.8M $-7.7M
← Newer Page 1 of 3 Older →